I will be trying to add 1% to this position around 13 cents p/share for a test on the recent bottom. If breaks, will drop to the bottom of the wedge as we try to create the wave 5 of retracement. Will look to add 0.5% if it does touch bottom of wedge. This will be a longterm play with anticipation to breakout of the wedge for a impulse.
LABD is finally perking up. Buying it as a hedge. chart starting to look good
TORNTPHARMA SWING AND BREAKOUT TRADING IDEA FRIENDS IF YOU LIKE THEN PLEASE LIKE AND SHARE.
Formations drawn Rising Wedge Scythe I expect a breakdown of this weird wedge that has formed between a major trendline and a line of strong bounce areas
breakout with volume short term upside ? comment, hit like if you think so
Detail @ The Chart
One can trade in this script with immediate target of 570 followed by 610 and higher before stock split, keep stop loss at 500. Good luck and have a great profitable day. For long term investors keep it in your portfolio and hold for multi fold returns. for more you can visit my site 5nancial.blogspot.com
GUFIC BIO PERFECT ROUNDING BOTTOM PATTERN ON CHARTS, PERFECT PICK FOR MEDIUM TERM INVESTMENTS. CMP -78
The price failed to break our support zone so many times, it seems like that is an area where buyers are stepping in and push the price higher any other ideas?? please comment your idea
Placing was at 6.15p Jupiter fund seller out - TR1 to confirm BoD own 11% of the company Acquisition of hVIVO back in December 2019 New presentation online at £28.6m mcap we are undervalued I have 8p as 1st target but we could breakout eventually & head to 9.15p then pullback to 8p & continue the bull trend after. Will re-evaluate once we hit 8p. Company looks...
Renko price movement above ATR and a strong move.
21-May-20 16:10 ET AMRN Amarin announces trial to evaluate effects of VASCEPA on patients with COVID-19 (7.28 -0.18) Amarin today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial primary endpoint is the effect of...
WOW, looks pretty cool. Do I want it though, not right now, no... Its starting to build up is how I look at it. From 3.75 to 4.15 is amazing buying power for you to actually make some AMAZING gains.... Invest Smart Can't predict the future but it looks promising...
Two reasons for posting this chart. 1) MNK is a long standing established generic and specialty manufacturer with products that have real usage. This is NOT a one hit wonder biotech. It would be bought out before full bankruptcy. 2) More importantly, when was the last time you've seen a CLEAR bullish divergence on a MONTHLY chart? This will be a bag I hold...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect...
🧑⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of...